Indenolol (BioDeep_00000180000)

   

human metabolite blood metabolite


代谢物信息卡片


1-(1H-inden-4-yloxy)-3-[(propan-2-yl)amino]propan-2-ol

化学式: C15H21NO2 (247.15722060000002)
中文名称: 茚诺洛尔
谱图信息: 最多检出来源 Mus musculus(blood) 66.67%

分子结构信息

SMILES: CC(C)NCC(COC1=CC=CC2=C1C=CC2)O
InChI: InChI=1S/C15H21NO2/c1-11(2)16-9-13(17)10-18-15-8-4-6-12-5-3-7-14(12)15/h3-4,6-8,11,13,16-17H,5,9-10H2,1-2H3

描述信息

C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist
D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists
D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents
D002317 - Cardiovascular Agents > D000889 - Anti-Arrhythmia Agents
D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents

同义名列表

11 个代谢物同义名

1-(1H-inden-4-yloxy)-3-[(propan-2-yl)amino]propan-2-ol; 1-(1H-inden-4-yloxy)-3-(isopropylamino)propan-2-ol; 1-(7-Indenyloxy)-3-isopropylaminopropan-2-ol.hcl; Indenolol, HCL(+-)-isomer; Indenolol, HCL(+)-isomer; Indenolol, HCL(S)-isomer; Indenolol, HCL(R)-isomer; INDENOLOL hydrochloride; SCH 28316Z; indenolol; YB-2



数据库引用编号

8 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Yi Zhi, Jin Yang, Shengchao Tian, Fang Yuan, Yang Liu, Yi Zhang, Pinghua Sun, Bo Song, Zhiwen Chen. Quantitative structure-activity relationship studies on indenoisoquinoline topoisomerase I inhibitors as anticancer agents in human renal cell carcinoma cell line SN12C. International journal of molecular sciences. 2012; 13(5):6009-6025. doi: 10.3390/ijms13056009. [PMID: 22754346]
  • Ihsan Ergün, M Cenk Akbostanci, Başol Canbakan, Bilge Koçer, Arzu Ensari, Gökhan Nergizoglu, Kenan Keven. Minimal change nephrotic syndrome with stiff-person syndrome: is there a link?. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2005 Jul; 46(1):e11-4. doi: 10.1053/j.ajkd.2005.03.009. [PMID: 15983949]
  • L Poggesi, G Masotti, M Boddi, G G Neri Serneri. Effects of indenolol on blood pressure, lower limb blood flow, adrenergic reflexes, and plasma renin activity. Clinical pharmacology and therapeutics. 1987 Mar; 41(3):344-50. doi: 10.1038/clpt.1987.37. [PMID: 2880689]
  • F Mailland, G Groothold, A Poli, C Pantarotto. Indenolol kinetics versus pharmacodynamics in hypertension. Methods and findings in experimental and clinical pharmacology. 1986 Sep; 8(9):567-74. doi: NULL. [PMID: 2877127]
  • M Yamamoto, T Sakurada, K Yoshida, K Kaise, N Kaise, H Fukazawa, M Suzuki, T Nomura, Y Itagaki, S Saito. Effect of carteolol, indenolol and metoprolol on the thyroid hormone of hyperthyroid patients. The Tohoku journal of experimental medicine. 1985 Aug; 146(4):385-90. doi: 10.1620/tjem.146.385. [PMID: 2866611]
  • R Sega, F Mailland, F Colombo, G Groothold, C Pantarotto, G Guenzati, A Libretti. Indenolol pharmacokinetics and pharmacodynamics after single and repeated daily doses. Journal of clinical pharmacology. 1985 Jul; 25(5):337-42. doi: 10.1002/j.1552-4604.1985.tb02851.x. [PMID: 4031110]
  • H Kato, J Kurihara, Y Takata, H Kunugi, Y Miyajima. Effects of prolonged administration of indenolol in hypertensive rats. Archives internationales de pharmacodynamie et de therapie. 1983 Jul; 264(1):82-95. doi: NULL. [PMID: 6138007]